{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:06:26Z","timestamp":1793070386620,"version":"4.5.0"},"reference-count":227,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Invited update on the management of systemic autoimmune Graves disease (GD) and associated Graves orbitopathy (GO).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Evidence acquisition<\/jats:title>\n                  <jats:p>Guidelines, pertinent original articles, systemic reviews, and meta-analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Evidence synthesis<\/jats:title>\n                  <jats:p>Thyrotropin receptor antibodies (TSH-R-Abs), foremost the stimulatory TSH-R-Abs, are a specific biomarker for GD. Their measurement assists in the differential diagnosis of hyperthyroidism and offers accurate and rapid diagnosis of GD. Thyroid ultrasound is a sensitive imaging tool for GD. Worldwide, thionamides are the favored treatment (12-18 months) of newly diagnosed GD, with methimazole (MMI) as the preferred drug. Patients with persistently high TSH-R-Abs and\/or persistent hyperthyroidism at 18 months, or with a relapse after completing a course of MMI, can opt for a definitive therapy with radioactive iodine (RAI) or total thyroidectomy (TX). Continued long-term, low-dose MMI administration is a valuable and safe alternative. Patient choice, both at initial presentation of GD and at recurrence, should be emphasized. Propylthiouracil is preferred to MMI during the first trimester of pregnancy. TX is best performed by a high-volume thyroid surgeon. RAI should be avoided in GD patients with active GO, especially in smokers. Recently, a promising therapy with an anti-insulin-like growth factor-1 monoclonal antibody for patients with active\/severe GO was approved by the Food and Drug Administration. COVID-19 infection is a risk factor for poorly controlled hyperthyroidism, which contributes to the infection\u2013related mortality risk. If GO is not severe, systemic steroid treatment should be postponed during COVID-19 while local treatment and preventive measures are offered.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A clear trend towards serological diagnosis and medical treatment of GD has emerged.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa646","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T23:34:12Z","timestamp":1600126452000},"page":"3704-3720","source":"Crossref","is-referenced-by-count":194,"title":["Management of Graves Thyroidal and Extrathyroidal Disease: An Update"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0441-430X","authenticated-orcid":false,"given":"George J","family":"Kahaly","sequence":"first","affiliation":[{"name":"Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"issue":"6","key":"2021122106321195000_CIT0001","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/thy.2010.0417","article-title":"Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists","volume":"21","author":"Bahn Chair","year":"2011","journal-title":"Thyroid."},{"issue":"4","key":"2021122106321195000_CIT0002","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the management of Graves\u2019 hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J."},{"issue":"12","key":"2021122106321195000_CIT0003","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrendo.2013.193","article-title":"Diagnosis and management of Graves disease: a global overview","volume":"9","author":"Bartalena","year":"2013","journal-title":"Nat Rev Endocrinol."},{"issue":"5","key":"2021122106321195000_CIT0004","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/cen.12060","article-title":"Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005","volume":"78","author":"Nystr\u00f6m","year":"2013","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"15","key":"2021122106321195000_CIT0005","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jama.2013.285606","article-title":"Variation in rates of autoimmune thyroid disease by race\/ethnicity in US military personnel","volume":"311","author":"McLeod","year":"2014","journal-title":"JAMA."},{"issue":"3","key":"2021122106321195000_CIT0006","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0031-1271619","article-title":"Increased familial clustering of autoimmune thyroid diseases","volume":"43","author":"Dittmar","year":"2011","journal-title":"Horm Metab Res."},{"issue":"10","key":"2021122106321195000_CIT0007","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2019-00602","article-title":"Autoimmune polyendocrinopathy","volume":"104","author":"Frommer","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122106321195000_CIT0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40618-017-0740-9","article-title":"Polyglandular autoimmune syndromes","volume":"41","author":"Kahaly","year":"2018","journal-title":"J Endocrinol Invest."},{"issue":"6","key":"2021122106321195000_CIT0009","doi-asserted-by":"crossref","first-page":"101344","DOI":"10.1016\/j.beem.2019.101344","article-title":"Autoimmune polyglandular diseases","volume":"33","author":"Kahaly","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"2","key":"2021122106321195000_CIT0010","first-page":"930","article-title":"Evidence for a major role of heredity in Graves\u2019 disease: a population-based study of two Danish twin cohorts","volume":"86","author":"Brix","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122106321195000_CIT0011","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1365-2265.2003.01862.x","article-title":"Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease","volume":"59","author":"Strieder","year":"2003","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"5","key":"2021122106321195000_CIT0012","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2796.1991.tb00368.x","article-title":"High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves\u2019 disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland","volume":"229","author":"Laurberg","year":"1991","journal-title":"J Intern Med."},{"issue":"5","key":"2021122106321195000_CIT0013","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archinte.160.5.661","article-title":"Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study","volume":"160","author":"Brix","year":"2000","journal-title":"Arch Intern Med."},{"issue":"10","key":"2021122106321195000_CIT0014","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid."},{"issue":"10","key":"2021122106321195000_CIT0015","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1210\/jc.2018-00509","article-title":"Stimulatory TSH-receptor antibodies and oxidative stress in Graves disease","volume":"103","author":"Diana","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122106321195000_CIT0016","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000504509","article-title":"Comparison of a novel homogeneous cyclic amp assay and a luciferase assay for measuring stimulating thyrotropin-receptor autoantibodies","volume":"9","author":"Diana","year":"2020","journal-title":"Eur Thyroid J."},{"issue":"1","key":"2021122106321195000_CIT0017","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves\u2019 disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Primers."},{"issue":"1","key":"2021122106321195000_CIT0018","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4158\/EP-2019-0363","article-title":"TSH receptor antibodies: relevance & utility","volume":"26","author":"Kahaly","year":"2020","journal-title":"Endocr Pract."},{"issue":"9","key":"2021122106321195000_CIT0019","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.amjmed.2012.05.013","article-title":"Laboratory testing in hyperthyroidism","volume":"125","author":"Grebe","year":"2012","journal-title":"Am J Med."},{"issue":"3","key":"2021122106321195000_CIT0020","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archinte.1989.00390030032006","article-title":"Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients","volume":"149","author":"de los Santos","year":"1989","journal-title":"Arch Intern Med."},{"issue":"2","key":"2021122106321195000_CIT0021","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1210\/jcem-70-2-453","article-title":"Applications of a new chemiluminometric thyrotropin assay to subnormal measurement","volume":"70","author":"Spencer","year":"1990","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122106321195000_CIT0022","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/cen.12688","article-title":"A 2013 European survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"84","author":"Bartalena","year":"2016","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"2","key":"2021122106321195000_CIT0023","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1056\/NEJMc1614624","article-title":"Graves\u2019 disease","volume":"376","author":"Kahaly","year":"2017","journal-title":"N Engl J Med."},{"key":"2021122106321195000_CIT0024","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fendo.2017.00028","article-title":"TSH receptor antibody functionality and nomenclature","volume":"8","author":"Kahaly","year":"2017","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"2","key":"2021122106321195000_CIT0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.autrev.2012.07.003","article-title":"TSH receptor autoantibody immunoassay in patients with Graves\u2019 disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis","volume":"12","author":"Tozzoli","year":"2012","journal-title":"Autoimmun Rev."},{"issue":"3","key":"2021122106321195000_CIT0026","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2249.2010.04266.x","article-title":"Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins","volume":"162","author":"Lytton","year":"2010","journal-title":"Clin Exp Immunol."},{"issue":"2","key":"2021122106321195000_CIT0027","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1309\/AJCPZUT7CNUEU7OP","article-title":"Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins","volume":"139","author":"Leschik","year":"2013","journal-title":"Am J Clin Pathol."},{"issue":"3","key":"2021122106321195000_CIT0028","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cei.12129","article-title":"A novel bioassay for anti-thyrotrophin receptor autoantibodies detects both thyroid-blocking and stimulating activity","volume":"173","author":"Li","year":"2013","journal-title":"Clin Exp Immunol."},{"issue":"1","key":"2021122106321195000_CIT0029","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000371740","article-title":"Rapid bioassay for detection of thyroid-stimulating antibodies using cyclic adenosine monophosphate-gated calcium channel and aequorin","volume":"4","author":"Araki","year":"2015","journal-title":"Eur Thyroid J."},{"issue":"1","key":"2021122106321195000_CIT0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000375445","article-title":"Bioassays for TSH receptor antibodies: Quo Vadis?","volume":"4","author":"Kahaly","year":"2015","journal-title":"Eur Thyroid J."},{"issue":"2","key":"2021122106321195000_CIT0031","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/thy.2014.0346","article-title":"Standardization of a bioassay for thyrotropin receptor stimulating autoantibodies","volume":"25","author":"Diana","year":"2015","journal-title":"Thyroid."},{"issue":"5","key":"2021122106321195000_CIT0032","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1089\/thy.2015.0447","article-title":"Analytical performance and validation of a bioassay for thyroid-blocking antibodies","volume":"26","author":"Diana","year":"2016","journal-title":"Thyroid."},{"issue":"3","key":"2021122106321195000_CIT0033","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12980","article-title":"Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease","volume":"189","author":"Diana","year":"2017","journal-title":"Clin Exp Immunol."},{"issue":"10","key":"2021122106321195000_CIT0034","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40618-016-0478-9","article-title":"Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies","volume":"39","author":"Diana","year":"2016","journal-title":"J Endocrinol Invest."},{"issue":"5","key":"2021122106321195000_CIT0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000478522","article-title":"Performance and specificity of 6 immunoassays for TSH receptor antibodies: a multicenter study","volume":"6","author":"Diana","year":"2017","journal-title":"Eur Thyroid J."},{"issue":"6","key":"2021122106321195000_CIT0036","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/a-0914-0535","article-title":"Comparison of a bridge immunoassay with two bioassays for thyrotropin receptor antibody detection and differentiation","volume":"51","author":"Allelein","year":"2019","journal-title":"Horm Metab Res."},{"issue":"5","key":"2021122106321195000_CIT0037","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1210\/jc.2009-2470","article-title":"A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves\u2019 orbitopathy","volume":"95","author":"Lytton","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021122106321195000_CIT0038","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.ophtha.2011.03.030","article-title":"Clinical relevance of thyroid-stimulating immunoglobulins in Graves\u2019 ophthalmopathy","volume":"118","author":"Ponto","year":"2011","journal-title":"Ophthalmology."},{"issue":"5","key":"2021122106321195000_CIT0039","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1210\/jc.2013-4026","article-title":"Clinical relevance of thyroid-stimulating autoantibodies in pediatric Graves\u2019 disease-a multicenter study","volume":"99","author":"Diana","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021122106321195000_CIT0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40618-015-0254-2","article-title":"Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy","volume":"38","author":"Ponto","year":"2015","journal-title":"J Endocrinol Invest."},{"key":"2021122106321195000_CIT0041","doi-asserted-by":"crossref","first-page":"678194","DOI":"10.1155\/2015\/678194","article-title":"Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbitopathy: a prospective study","volume":"2015","author":"Kampmann","year":"2015","journal-title":"Int J Endocrinol."},{"issue":"5","key":"2021122106321195000_CIT0042","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1210\/jc.2016-1220","article-title":"Thyroid stimulating antibodies are highly prevalent in Hashimoto\u2019s thyroiditis and associated orbitopathy","volume":"101","author":"Kahaly","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122106321195000_CIT0043","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/08916934.2018.1431776","article-title":"Functional TSH receptor antibodies in children with autoimmune thyroid diseases","volume":"51","author":"Sto\u017cek","year":"2018","journal-title":"Autoimmunity."},{"issue":"1","key":"2021122106321195000_CIT0044","first-page":"6","article-title":"Fetal\/neonatal thyrotoxicosis in a newborn from a hypothyroid woman with Hashimoto thyroiditis","volume":"102","author":"Kiefer","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021122106321195000_CIT0045","doi-asserted-by":"crossref","first-page":"767","DOI":"10.7326\/L19-0818","article-title":"Graves Disease with thyroid-stimulating hormone receptor-blocking autoantibodies during pregnancy","volume":"172","author":"Decallonne","year":"2020","journal-title":"Ann Intern Med."},{"key":"2021122106321195000_CIT0046","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/ct.2017;29.32-34","article-title":"Fetal hyperthyroidism resulted from TSI in a mother with Hashimoto\u2019s hypothyroidism","volume":"29","author":"Mestman","year":"2017","journal-title":"Clin Thyroidol."},{"issue":"1","key":"2021122106321195000_CIT0047","first-page":"e1","article-title":"TSI assay utilization: impact on costs of Graves\u2019 hyperthyroidism diagnosis","volume":"18","author":"McKee","year":"2012","journal-title":"Am J Manag Care."},{"issue":"6","key":"2021122106321195000_CIT0048","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/thy.2011.2106.ed3","article-title":"The American Thyroid Association\/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective","volume":"21","author":"Kahaly","year":"2011","journal-title":"Thyroid."},{"issue":"2","key":"2021122106321195000_CIT0049","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1530\/acta.0.1260128","article-title":"Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves\u2019 disease","volume":"126","author":"Vitti","year":"1992","journal-title":"Acta Endocrinol (Copenh)."},{"issue":"2","key":"2021122106321195000_CIT0050","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0889-8529(05)70190-0","article-title":"Thyroid ultrasound","volume":"30","author":"Heged\u00fcs","year":"2001","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"3","key":"2021122106321195000_CIT0051","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/thy.2006.0104","article-title":"Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism","volume":"17","author":"Erdo\u011fan","year":"2007","journal-title":"Thyroid."},{"issue":"4","key":"2021122106321195000_CIT0052","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2214\/ajr.150.4.781","article-title":"Color-flow Doppler sonography in Graves disease: \u201cthyroid inferno\u201d","volume":"150","author":"Ralls","year":"1988","journal-title":"AJR Am J Roentgenol."},{"issue":"12","key":"2021122106321195000_CIT0053","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","article-title":"A 2011 survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"97","author":"Burch","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021122106321195000_CIT0054","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/thy.2016.0222","article-title":"Antithyroid drugs-the most common treatment for Graves\u2019 disease in the United States: a nationwide population-based study","volume":"26","author":"Brito","year":"2016","journal-title":"Thyroid."},{"issue":"1","key":"2021122106321195000_CIT0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the management of Graves\u2019 orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J."},{"key":"2021122106321195000_CIT0056","first-page":"CD010094","article-title":"Radioiodine therapy versus antithyroid medications for Graves\u2019 disease","volume":"2","author":"Ma","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"2021122106321195000_CIT0057","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12902-018-0322-7","article-title":"Radioiodine treatment for graves\u2019 disease: a 10-year Australian cohort study","volume":"18","author":"Fanning","year":"2018","journal-title":"BMC Endocr Disord."},{"issue":"2","key":"2021122106321195000_CIT0058","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","article-title":"Relation between therapy for hyperthyroidism and the course of Graves\u2019 ophthalmopathy","volume":"338","author":"Bartalena","year":"1998","journal-title":"N Engl J Med."},{"issue":"26","key":"2021122106321195000_CIT0059","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","article-title":"Occurrence of ophthalmopathy after treatment for Graves\u2019 hyperthyroidism. The Thyroid Study Group","volume":"326","author":"Tallstedt","year":"1992","journal-title":"N Engl J Med."},{"issue":"10","key":"2021122106321195000_CIT0060","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1210\/jc.2009-0747","article-title":"Thyroid-associated ophthalmopathy after treatment for Graves\u2019 hyperthyroidism with antithyroid drugs or iodine-131","volume":"94","author":"Tr\u00e4isk","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021122106321195000_CIT0061","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s40618-016-0484-y","article-title":"Relation between therapy options for Graves\u2019 disease and the course of Graves\u2019 ophthalmopathy: a systematic review and meta-analysis","volume":"39","author":"Li","year":"2016","journal-title":"J Endocrinol Invest."},{"issue":"1","key":"2021122106321195000_CIT0062","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EJE-07-0450","article-title":"TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study","volume":"158","author":"Laurberg","year":"2008","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2021122106321195000_CIT0063","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1210\/endo-103-3-871","article-title":"The irreversible inactivation of thyroid peroxidase by methylmercaptoimidazole, thiouracil, and propylthiouracil in vitro and its relationship to in vivo findings","volume":"103","author":"Davidson","year":"1978","journal-title":"Endocrinology."},{"issue":"1","key":"2021122106321195000_CIT0064","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/endo-99-1-281","article-title":"Formation of 3,3\u2019-diiodothyronine and 3\u2019,5\u2019,3-triiodothyronine (reverse T3) in thyroid glands of rats and in enzymatically iodinated thyroglobulin","volume":"99","author":"Taurog","year":"1976","journal-title":"Endocrinology."},{"issue":"3","key":"2021122106321195000_CIT0065","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1124\/jpet.107.132407","article-title":"Thionamides inhibit the transcription factor nuclear factor-kappaB by suppression of Rac1 and inhibitor of kappaB kinase alpha","volume":"324","author":"Humar","year":"2008","journal-title":"J Pharmacol Exp Ther."},{"issue":"1","key":"2021122106321195000_CIT0066","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198701013160104","article-title":"Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves\u2019 disease","volume":"316","author":"T\u00f6tterman","year":"1987","journal-title":"N Engl J Med."},{"issue":"6","key":"2021122106321195000_CIT0067","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/105072501750302886","article-title":"Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves\u2019 disease","volume":"11","author":"Zantut-Wittmann","year":"2001","journal-title":"Thyroid."},{"issue":"2","key":"2021122106321195000_CIT0068","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1530\/acta.0.1120210","article-title":"Inhibitory effects of antithyroid drugs on oxygen radical formation in human neutrophils","volume":"112","author":"Imamura","year":"1986","journal-title":"Acta Endocrinol (Copenh)."},{"issue":"6416","key":"2021122106321195000_CIT0069","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bmj.288.6416.518","article-title":"Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression","volume":"288","author":"Weetman","year":"1984","journal-title":"Br Med J (Clin Res Ed)."},{"issue":"6","key":"2021122106321195000_CIT0070","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1124\/mol.60.6.1165","article-title":"Old drugs learn new tricks: insights from mammalian trace amine receptors","volume":"60","author":"Kim","year":"2001","journal-title":"Mol Pharmacol."},{"issue":"1","key":"2021122106321195000_CIT0071","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1210\/jcem-57-1-129","article-title":"Intrathyroidal concentrations of methimazole in patients with Graves\u2019 disease","volume":"57","author":"Jansson","year":"1983","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122106321195000_CIT0072","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0304-4165(80)90299-8","article-title":"Study on the enzymatic 5\u2019-deiodination of 3\u2019,5\u2019-diiodothyronine using a radioimmunoassay for 3\u2019-iodothyronine","volume":"631","author":"Visser","year":"1980","journal-title":"Biochim Biophys Acta."},{"issue":"8","key":"2021122106321195000_CIT0073","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1089\/thy.2005.15.787","article-title":"Biochemical mechanisms of thyroid hormone deiodination","volume":"15","author":"Kuiper","year":"2005","journal-title":"Thyroid."},{"issue":"9","key":"2021122106321195000_CIT0074","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","article-title":"Antithyroid drugs","volume":"352","author":"Cooper","year":"2005","journal-title":"N Engl J Med."},{"issue":"8","key":"2021122106321195000_CIT0075","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1210\/jc.2003-030185","article-title":"Antithyroid drugs in the management of patients with Graves\u2019 disease: an evidence-based approach to therapeutic controversies","volume":"88","author":"Cooper","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021122106321195000_CIT0076","first-page":"505","article-title":"Comparative bioavailability of carbimazole and methimazole","volume":"21","author":"Jansson","year":"1983","journal-title":"Int J Clin Pharmacol Ther Toxicol."},{"issue":"11","key":"2021122106321195000_CIT0077","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1210\/jc.2013-2831","article-title":"Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study","volume":"98","author":"Andersen","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122106321195000_CIT0078","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S2213-8587(13)70086-X","article-title":"Hyperthyroidism in pregnancy","volume":"1","author":"Cooper","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"2021122106321195000_CIT0079","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0889-8529(18)30165-8","article-title":"Life-threatening thyrotoxicosis. Thyroid storm","volume":"22","author":"Burch","year":"1993","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"1","key":"2021122106321195000_CIT0080","first-page":"CD003420","article-title":"Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism","author":"Abraham","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"2021122106321195000_CIT0081","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJM199601253340403","article-title":"Lack of effect of thyroxine in patients with Graves\u2019 hyperthyroidism who are treated with an antithyroid drug","volume":"334","author":"McIver","year":"1996","journal-title":"N Engl J Med."},{"issue":"5","key":"2021122106321195000_CIT0082","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2265.1998.00466.x","article-title":"TSH suppression combined with carbimazole for Graves\u2019 disease: effect on remission and relapse rates","volume":"48","author":"Pujol","year":"1998","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"3","key":"2021122106321195000_CIT0083","first-page":"814","article-title":"Effect of methimazole, with or without L-thyroxine, on remission rates in Graves\u2019 disease","volume":"83","author":"Rittmaster","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122106321195000_CIT0084","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/eje.0.1440475","article-title":"Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves\u2019 hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study","volume":"144","author":"Glinoer","year":"2001","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2021122106321195000_CIT0085","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1507\/endocrj.K05-121","article-title":"TSH receptor antibody measurements and prediction of remission in Graves\u2019 disease patients treated with minimum maintenance doses of antithyroid drugs","volume":"53","author":"Okamoto","year":"2006","journal-title":"Endocr J."},{"issue":"3","key":"2021122106321195000_CIT0086","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","article-title":"Clinical features of patients with Graves\u2019 disease undergoing remission after antithyroid drug treatment","volume":"7","author":"Vitti","year":"1997","journal-title":"Thyroid."},{"issue":"2","key":"2021122106321195000_CIT0087","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343979","article-title":"Does smoking increase relapse rates in Graves\u2019 disease?","volume":"25","author":"Kimball","year":"2002","journal-title":"J Endocrinol Invest."},{"issue":"10","key":"2021122106321195000_CIT0088","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1210\/jc.2008-0966","article-title":"The effect of pregnancy on subsequent relapse from Graves\u2019 disease after a successful course of antithyroid drug therapy","volume":"93","author":"Rotondi","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021122106321195000_CIT0089","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1089\/thy.2016.0652","article-title":"Long-term antithyroid drug treatment: a systematic review and meta-analysis","volume":"27","author":"Azizi","year":"2017","journal-title":"Thyroid."},{"issue":"4","key":"2021122106321195000_CIT0090","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1210\/jc.2015-3644","article-title":"Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves\u2019 hyperthyroidism","volume":"101","author":"Vos","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021122106321195000_CIT0091","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","article-title":"Antithyroid drug treatment for Graves\u2019 disease: baseline predictive models of relapse after treatment for a patient-tailored management","volume":"41","author":"Masiello","year":"2018","journal-title":"J Endocrinol Invest."},{"issue":"6","key":"2021122106321195000_CIT0092","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1210\/jc.2006-2135","article-title":"Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves\u2019 disease","volume":"92","author":"Nakamura","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122106321195000_CIT0093","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S2213-8587(20)30025-5","article-title":"Methimazole and risk of acute pancreatitis","volume":"8","author":"Brix","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"2021122106321195000_CIT0094","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/ct.2020;32.327-329","article-title":"The association between thionamides and acute pancreatitis","volume":"32","author":"Cooper","year":"2020","journal-title":"Clin Thyroidol"},{"key":"2021122106321195000_CIT0095","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2019.0589","article-title":"Association between thionamides and acute pancreatitis: a case-control study","author":"Guo","year":"2020","journal-title":"Thyroid."},{"issue":"3","key":"2021122106321195000_CIT0096","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archinte.1990.00390150107020","article-title":"Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring","volume":"150","author":"Tajiri","year":"1990","journal-title":"Arch Intern Med."},{"issue":"12","key":"2021122106321195000_CIT0097","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1210\/jc.2013-2569","article-title":"Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan","volume":"98","author":"Nakamura","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021122106321195000_CIT0098","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/qjmed\/92.8.455","article-title":"Antithyroid-drug-induced agranulocytosis complicated by life-threatening infections","volume":"92","author":"Sheng","year":"1999","journal-title":"QJM."},{"issue":"6","key":"2021122106321195000_CIT0099","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/thy.2008.0364","article-title":"Methimazole-induced agranulocytosis in patients with Graves\u2019 disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily","volume":"19","author":"Takata","year":"2009","journal-title":"Thyroid."},{"issue":"2","key":"2021122106321195000_CIT0100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2141.1986.tb04130.x","article-title":"Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells","volume":"64","author":"Fibbe","year":"1986","journal-title":"Br J Haematol."},{"issue":"1","key":"2021122106321195000_CIT0101","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1046\/j.1365-2249.2002.01720.x","article-title":"Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity","volume":"127","author":"Akamizu","year":"2002","journal-title":"Clin Exp Immunol."},{"issue":"2","key":"2021122106321195000_CIT0102","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/17425255.2015.985649","article-title":"Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis","volume":"11","author":"Johnston","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"2021122106321195000_CIT0103","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.1038\/ncomms8633","article-title":"Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study","volume":"6","author":"Chen","year":"2015","journal-title":"Nat Commun."},{"issue":"6","key":"2021122106321195000_CIT0104","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2213-8587(16)00113-3","article-title":"Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population","volume":"4","author":"Hallberg","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"2021122106321195000_CIT0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/ehm.11.12","article-title":"Clinical presentation and management of drug-induced agranulocytosis","volume":"4","author":"Andr\u00e8s","year":"2011","journal-title":"Expert Rev Hematol."},{"issue":"12","key":"2021122106321195000_CIT0106","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1089\/thy.2014.0603","article-title":"Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem?","volume":"25","author":"Balavoine","year":"2015","journal-title":"Thyroid."},{"issue":"3","key":"2021122106321195000_CIT0107","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4158\/EP.8.3.222","article-title":"Methimazole-induced hepatotoxicity","volume":"8","author":"Woeber","year":"2002","journal-title":"Endocr Pract."},{"issue":"3","key":"2021122106321195000_CIT0108","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1089\/thy.2014.0350","article-title":"Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China","volume":"25","author":"Yang","year":"2015","journal-title":"Thyroid."},{"issue":"3","key":"2021122106321195000_CIT0109","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/bcp.12336","article-title":"Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study","volume":"78","author":"Wang","year":"2014","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"2021122106321195000_CIT0110","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1440-1746.1995.tb01106.x","article-title":"Clinical associations between thyroid and liver diseases","volume":"10","author":"Huang","year":"1995","journal-title":"J Gastroenterol Hepatol."},{"issue":"3","key":"2021122106321195000_CIT0111","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/thy.2016.0457","article-title":"2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum","volume":"27","author":"Alexander","year":"2017","journal-title":"Thyroid."},{"issue":"6","key":"2021122106321195000_CIT0112","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2265.1984.tb00119.x","article-title":"Maternal hyperthyroidism and congenital malformation in the offspring","volume":"20","author":"Momotani","year":"1984","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"3","key":"2021122106321195000_CIT0113","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0028-2243(94)90276-3","article-title":"Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy","volume":"54","author":"Kriplani","year":"1994","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"issue":"4","key":"2021122106321195000_CIT0114","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/thy.2017.0425","article-title":"Maternal thyroid function in early pregnancy and child neurodevelopmental disorders: a Danish nationwide case-cohort study","volume":"28","author":"Andersen","year":"2018","journal-title":"Thyroid."},{"issue":"1","key":"2021122106321195000_CIT0115","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EJE-14-0135","article-title":"Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk?","volume":"171","author":"Laurberg","year":"2014","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2021122106321195000_CIT0116","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/(SICI)1096-8628(19990305)83:1<43::AID-AJMG8>3.0.CO;2-C","article-title":"Methimazole embryopathy: delineation of the phenotype","volume":"83","author":"Clementi","year":"1999","journal-title":"Am J Med Genet."},{"issue":"6","key":"2021122106321195000_CIT0117","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/M17-1398","article-title":"Antithyroid drugs and congenital malformations: a nationwide Korean cohort study","volume":"168","author":"Seo","year":"2018","journal-title":"Ann Intern Med."},{"issue":"12","key":"2021122106321195000_CIT0118","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1210\/jc.2019-01343","article-title":"Maternal thyroid function, use of antithyroid drugs in early pregnancy, and birth defects","volume":"104","author":"Andersen","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021122106321195000_CIT0119","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1089\/thy.2014.0150","article-title":"Severity of birth defects after propylthiouracil exposure in early pregnancy","volume":"24","author":"Andersen","year":"2014","journal-title":"Thyroid."},{"issue":"1","key":"2021122106321195000_CIT0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/thy.2018.0621","article-title":"Timing of shift in antithyroid drug therapy and birth defects","volume":"29","author":"Andersen","year":"2019","journal-title":"Thyroid."},{"issue":"9","key":"2021122106321195000_CIT0121","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/thy.2019.0180","article-title":"Increased remission rates after long-term methimazole therapy in patients with Graves\u2019 disease: results of a randomized clinical trial","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid."},{"issue":"6","key":"2021122106321195000_CIT0122","first-page":"1516","article-title":"A prospective randomized trial of antithyroid drug dose in Graves\u2019 disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment","volume":"76","author":"Reinwein","year":"1993","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122106321195000_CIT0123","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/thy.2014.0084","article-title":"Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg\/day and methimazole 30 mg\/day as initial therapy for Graves\u2019 disease patients with moderate to severe hyperthyroidism","volume":"25","author":"Sato","year":"2015","journal-title":"Thyroid."},{"issue":"11","key":"2021122106321195000_CIT0124","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40618-019-01054-1","article-title":"Safety of long-term antithyroid drug treatment? A systematic review","volume":"42","author":"Azizi","year":"2019","journal-title":"J Endocrinol Invest."},{"issue":"9","key":"2021122106321195000_CIT0125","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/thy.2011.0039","article-title":"Sustained control of Graves\u2019 hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves\u2019 orbitopathy","volume":"21","author":"Laurberg","year":"2011","journal-title":"Thyroid."},{"issue":"5","key":"2021122106321195000_CIT0126","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/eje.1.01904","article-title":"Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine","volume":"152","author":"Azizi","year":"2005","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2021122106321195000_CIT0127","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/thy.2010.0181","article-title":"Outcome of very long-term treatment with antithyroid drugs in Graves\u2019 hyperthyroidism associated with Graves\u2019 orbitopathy","volume":"21","author":"Elbers","year":"2011","journal-title":"Thyroid."},{"issue":"12","key":"2021122106321195000_CIT0128","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1089\/thy.2015.0195","article-title":"Outcomes in relapsed Graves\u2019 disease patients following radioiodine or prolonged low dose of methimazole treatment","volume":"25","author":"Villagelin","year":"2015","journal-title":"Thyroid."},{"issue":"15","key":"2021122106321195000_CIT0129","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1056\/NEJMc0809750","article-title":"Ending propylthiouracil-induced liver failure in children","volume":"360","author":"Rivkees","year":"2009","journal-title":"N Engl J Med."},{"issue":"3","key":"2021122106321195000_CIT0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000438750","article-title":"The 2015 European Thyroid Association Guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism","volume":"4","author":"Biondi","year":"2015","journal-title":"Eur Thyroid J."},{"issue":"9","key":"2021122106321195000_CIT0131","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.112.096024","article-title":"Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts","volume":"126","author":"Gencer","year":"2012","journal-title":"Circulation."},{"issue":"10","key":"2021122106321195000_CIT0132","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/archinternmed.2012.402","article-title":"Subclinical hyperthyroidism and the risk of coronary heart disease and mortality","volume":"172","author":"Collet","year":"2012","journal-title":"Arch Intern Med."},{"issue":"20","key":"2021122106321195000_CIT0133","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1001\/jama.2015.5161","article-title":"Subclinical thyroid dysfunction and fracture risk: a meta-analysis","volume":"313","author":"Blum","year":"2015","journal-title":"JAMA."},{"issue":"6","key":"2021122106321195000_CIT0134","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1089\/thy.2015.0470","article-title":"The natural history of subclinical hyperthyroidism in Graves\u2019 disease: the rule of thirds","volume":"26","author":"Zhyzhneuskaya","year":"2016","journal-title":"Thyroid."},{"issue":"5","key":"2021122106321195000_CIT0135","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1210\/er.2003-0033","article-title":"Thyroid hormone action in the heart","volume":"26","author":"Kahaly","year":"2005","journal-title":"Endocr Rev."},{"issue":"8","key":"2021122106321195000_CIT0136","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrendo.2010.105","article-title":"Cardiovascular involvement in patients with different causes of hyperthyroidism","volume":"6","author":"Biondi","year":"2010","journal-title":"Nat Rev Endocrinol."},{"issue":"3","key":"2021122106321195000_CIT0137","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2021122106321195000_CIT0138","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0002-9343(83)91217-2","article-title":"Radioiodine-induced thyroid storm. Case report and literature review","volume":"75","author":"McDermott","year":"1983","journal-title":"Am J Med."},{"issue":"7","key":"2021122106321195000_CIT0139","first-page":"3016","article-title":"The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves\u2019 disease","volume":"86","author":"Burch","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122106321195000_CIT0140","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMct1007101","article-title":"Radioiodine therapy for hyperthyroidism","volume":"364","author":"Ross","year":"2011","journal-title":"N Engl J Med."},{"issue":"1","key":"2021122106321195000_CIT0141","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/cen.13873","article-title":"Predicting outcomes and complications following radioiodine therapy in Graves\u2019 thyrotoxicosis","volume":"90","author":"Aung","year":"2019","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"11","key":"2021122106321195000_CIT0142","first-page":"4012","article-title":"Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves\u2019 hyperthyroidism","volume":"84","author":"Andrade","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122106321195000_CIT0143","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv314","article-title":"Use of radioactive iodine for thyroid cancer and risk of second primary malignancy: a nationwide population-based study","volume":"108","author":"Teng","year":"2016","journal-title":"J Natl Cancer Inst."},{"issue":"10","key":"2021122106321195000_CIT0144","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/cncr.22635","article-title":"Increased cancer incidence after radioiodine treatment for hyperthyroidism","volume":"109","author":"Metso","year":"2007","journal-title":"Cancer."},{"issue":"5","key":"2021122106321195000_CIT0145","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/ERC-12-0176","article-title":"Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis","volume":"19","author":"Hieu","year":"2012","journal-title":"Endocr Relat Cancer."},{"issue":"10","key":"2021122106321195000_CIT0146","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1210\/jc.2015-1874","article-title":"Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism","volume":"100","author":"Ry\u00f6di","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021122106321195000_CIT0147","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jamainternmed.2019.0981","article-title":"Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism","volume":"179","author":"Kitahara","year":"2019","journal-title":"JAMA Intern Med."},{"issue":"7","key":"2021122106321195000_CIT0148","doi-asserted-by":"crossref","first-page":"e209660","DOI":"10.1001\/jamanetworkopen.2020.9660","article-title":"Association of radioactive iodine, antithyroid drug, and surgical treatments with solid cancer mortality in patients with hyperthyroidism","volume":"3","author":"Kitahara","year":"2020","journal-title":"JAMA Netw Open."},{"issue":"2","key":"2021122106321195000_CIT0149","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/thy.2019.0205","article-title":"Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study","volume":"30","author":"Gronich","year":"2020","journal-title":"Thyroid."},{"issue":"10047","key":"2021122106321195000_CIT0150","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","article-title":"Hyperthyroidism","volume":"388","author":"De Leo","year":"2016","journal-title":"Lancet."},{"issue":"1","key":"2021122106321195000_CIT0151","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.surg.2017.03.030","article-title":"Impact of potassium iodide on thyroidectomy for Graves\u2019 disease: implications for safety and operative difficulty","volume":"163","author":"Randle","year":"2018","journal-title":"Surgery."},{"issue":"2","key":"2021122106321195000_CIT0152","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1245\/s10434-012-2606-x","article-title":"What is the best definitive treatment for Graves\u2019 disease? A systematic review of the existing literature","volume":"20","author":"Genovese","year":"2013","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"2021122106321195000_CIT0153","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.surg.2013.04.068","article-title":"The impact of surgical volume on patient outcomes following thyroid surgery","volume":"154","author":"Kandil","year":"2013","journal-title":"Surgery."},{"issue":"12","key":"2021122106321195000_CIT0154","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1245\/s10434-014-3846-8","article-title":"Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons","volume":"21","author":"Hauch","year":"2014","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"2021122106321195000_CIT0155","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00104-014-2819-6","article-title":"Surgical assessment of complications after thyroid gland operations","volume":"86","author":"Dralle","year":"2015","journal-title":"Chirurg."},{"issue":"3","key":"2021122106321195000_CIT0156","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1245\/s10434-014-4077-8","article-title":"Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study","volume":"22","author":"Oltmann","year":"2015","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"2021122106321195000_CIT0157","doi-asserted-by":"crossref","first-page":"e14455","DOI":"10.1097\/MD.0000000000014455","article-title":"Role of oral calcium supplementation alone or with vitamin D in preventing post-thyroidectomy hypocalcaemia: a meta-analysis","volume":"98","author":"Xing","year":"2019","journal-title":"Medicine (Baltimore)."},{"issue":"12","key":"2021122106321195000_CIT0158","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1089\/thy.2014.0111","article-title":"A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease","volume":"24","author":"Di Donna","year":"2014","journal-title":"Thyroid."},{"issue":"1","key":"2021122106321195000_CIT0159","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jamcollsurg.2015.10.005","article-title":"Prospective intervention of a novel levothyroxine dosing protocol based on body mass index after thyroidectomy","volume":"222","author":"Elfenbein","year":"2016","journal-title":"J Am Coll Surg."},{"issue":"2","key":"2021122106321195000_CIT0160","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves orbitopathy","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat Rev Endocrinol."},{"key":"2021122106321195000_CIT0161","article-title":"Thyrotropin receptor antibodies and Graves\u2019 orbitopathy","author":"Diana","year":"2020","journal-title":"J Endocrinol Invest."},{"issue":"3","key":"2021122106321195000_CIT0162","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves\u2019 orbitopathy: the European Group on Graves\u2019 Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"Wiersinga","year":"2006","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2021122106321195000_CIT0163","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1210\/clinem\/dgz292","article-title":"Prospective trial of functional thyrotropin receptor antibodies in Graves disease","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021122106321195000_CIT0164","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1210\/jc.2018-02705","article-title":"High titers of thyrotropin receptor antibodies are associated with orbitopathy in patients with Graves disease","volume":"104","author":"Kahaly","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"20","key":"2021122106321195000_CIT0165","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves\u2019 orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med."},{"key":"2021122106321195000_CIT0166","doi-asserted-by":"crossref","DOI":"10.1159\/000475956","article-title":"Management of moderately severe graves\u2019 orbitopathy","volume-title":"Graves\u2019 Orbitopathy - A Multidisciplinary Approach Questions and Answers","author":"Kahaly","year":"2017","edition":"3"},{"issue":"4","key":"2021122106321195000_CIT0167","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000440834","article-title":"Methylprednisolone pulse treatment of Graves\u2019 ophthalmopathy is not associated with secondary adrenocortical insufficiency","volume":"4","author":"Jespersen","year":"2015","journal-title":"Eur Thyroid J."},{"issue":"2","key":"2021122106321195000_CIT0168","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021122106321195000_CIT0169","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/BF03346732","article-title":"Dose of intravenous steroids and therapy outcome in Graves\u2019 orbitopathy","volume":"34","author":"Zang","year":"2011","journal-title":"J Endocrinol Invest."},{"issue":"11","key":"2021122106321195000_CIT0170","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1210\/jc.2012-2758","article-title":"Efficacy and safety of orbital radiotherapy for graves\u2019 orbitopathy","volume":"97","author":"Tanda","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2021122106321195000_CIT0171","doi-asserted-by":"crossref","DOI":"10.1159\/isbn.978-3-318-06085-0","volume-title":"Graves\u2019 Orbitopathy a Multidisciplinary Approach","author":"Wiersinga","year":"2017","edition":"3"},{"issue":"8","key":"2021122106321195000_CIT0172","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med."},{"issue":"9","key":"2021122106321195000_CIT0173","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1210\/en.2013-1576","article-title":"Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves\u2019 orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation","volume":"154","author":"Moshkelgosha","year":"2013","journal-title":"Endocrinology."},{"issue":"2","key":"2021122106321195000_CIT0174","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1089\/thy.2018.0326","article-title":"Therapeutic effects of short cyclic and combined epitope peptides in a long-term model of Graves\u2019 disease and orbitopathy","volume":"29","author":"Fa\u00dfbender","year":"2019","journal-title":"Thyroid."},{"issue":"4","key":"2021122106321195000_CIT0175","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/en.2014-1813","article-title":"Prolonged TSH receptor A subunit immunization of female mice leads to a long-term model of Graves\u2019 disease, tachycardia, and cardiac hypertrophy","volume":"156","author":"Holthoff","year":"2015","journal-title":"Endocrinology."},{"issue":"7","key":"2021122106321195000_CIT0176","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1210\/en.2016-1845","article-title":"Cyclic peptides for effective treatment in a long-term model of Graves disease and orbitopathy in female mice","volume":"158","author":"Holthoff","year":"2017","journal-title":"Endocrinology."},{"issue":"2","key":"2021122106321195000_CIT0177","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40618-019-01116-4","article-title":"Immunohistochemical analysis of human orbital tissue in Graves\u2019 orbitopathy","volume":"43","author":"Hai","year":"2020","journal-title":"J Endocrinol Invest."},{"issue":"12","key":"2021122106321195000_CIT0178","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1167\/iovs.06-0596","article-title":"Biological effects of thyrotropin receptor activation on human orbital preadipocytes","volume":"47","author":"Zhang","year":"2006","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"3","key":"2021122106321195000_CIT0179","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1167\/iovs.14-14002","article-title":"Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy","volume":"55","author":"Wang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"4","key":"2021122106321195000_CIT0180","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08916939309014643","article-title":"Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy","volume":"16","author":"Weightman","year":"1993","journal-title":"Autoimmunity."},{"issue":"6","key":"2021122106321195000_CIT0181","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol."},{"issue":"5","key":"2021122106321195000_CIT0182","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","article-title":"Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves\u2019 disease may carry functional consequences for disease pathogenesis","volume":"178","author":"Douglas","year":"2007","journal-title":"J Immunol."},{"issue":"1","key":"2021122106321195000_CIT0183","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev."},{"issue":"2","key":"2021122106321195000_CIT0184","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1210\/jc.2012-1771","article-title":"Autoantibodies to the IGF1 receptor in Graves\u2019 orbitopathy","volume":"98","author":"Minich","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122106321195000_CIT0185","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40618-018-0943-8","article-title":"Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves\u2019 disease and Graves\u2019 orbitopathy","volume":"42","author":"Marin\u00f2","year":"2019","journal-title":"J Endocrinol Invest."},{"issue":"6","key":"2021122106321195000_CIT0186","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1210\/jc.2016-1315","article-title":"TSH\/IGF-1 receptor cross talk in Graves\u2019 ophthalmopathy pathogenesis","volume":"101","author":"Krieger","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021122106321195000_CIT0187","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1210\/en.2017-00528","article-title":"TSH\/IGF-1 receptor cross-talk rapidly activates extracellular signal-regulated kinases in multiple cell types","volume":"158","author":"Krieger","year":"2017","journal-title":"Endocrinology."},{"issue":"6","key":"2021122106321195000_CIT0188","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1210\/en.2019-00055","article-title":"Arrestin-\u03b2-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk","volume":"160","author":"Krieger","year":"2019","journal-title":"Endocrinology."},{"issue":"5","key":"2021122106321195000_CIT0189","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/thy.2018.0089","article-title":"Evidence that Graves\u2019 ophthalmopathy immunoglobulins do not directly activate IGF-1 receptors","volume":"28","author":"Marcus-Samuels","year":"2018","journal-title":"Thyroid."},{"issue":"12","key":"2021122106321195000_CIT0190","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J Immunol."},{"issue":"6","key":"2021122106321195000_CIT0191","doi-asserted-by":"crossref","first-page":"e0130322","DOI":"10.1371\/journal.pone.0130322","article-title":"TSH-mediated TNF\u03b1 production in human fibrocytes is inhibited by teprotumumab, an IGF-1R antagonist","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One."},{"issue":"9","key":"2021122106321195000_CIT0192","doi-asserted-by":"crossref","first-page":"E1635","DOI":"10.1210\/jc.2014-1580","article-title":"Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes","volume":"99","author":"Chen","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"18","key":"2021122106321195000_CIT0193","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med."},{"issue":"4","key":"2021122106321195000_CIT0194","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med."},{"issue":"5","key":"2021122106321195000_CIT0195","doi-asserted-by":"crossref","first-page":"D27","DOI":"10.1530\/EJE-19-0389","article-title":"Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?","volume":"181","author":"Smith","year":"2019","journal-title":"Eur J Endocrinol."},{"issue":"20","key":"2021122106321195000_CIT0196","first-page":"1959","article-title":"Teprotumumab for active thyroid eye disease. Reply","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med."},{"issue":"8","key":"2021122106321195000_CIT0197","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40618-014-0097-2","article-title":"Extrathyroidal manifestations of Graves\u2019 disease: a 2014 update","volume":"37","author":"Bartalena","year":"2014","journal-title":"J Endocrinol Invest."},{"issue":"4","key":"2021122106321195000_CIT0198","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.beem.2011.10.001","article-title":"Thyroid dermopathy and acropachy","volume":"26","author":"Fatourechi","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"12","key":"2021122106321195000_CIT0199","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1210\/jc.2002-020746","article-title":"Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period","volume":"87","author":"Fatourechi","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122106321195000_CIT0200","first-page":"438","article-title":"Dermopathy of Graves\u2019 disease (pretibial myxedema): long-term outcome","volume":"87","author":"Schwartz","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122106321195000_CIT0201","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S2213-8587(19)30059-2","article-title":"Primary therapy of Graves\u2019 disease and cardiovascular morbidity and mortality: a linked-record cohort study","volume":"7","author":"Okosieme","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"2021122106321195000_CIT0202","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/thy.2017.0243","article-title":"Thyroid storm: a Japanese perspective","volume":"28","author":"Akamizu","year":"2018","journal-title":"Thyroid."},{"issue":"8","key":"2021122106321195000_CIT0203","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40618-020-01293-7","article-title":"Management of Graves\u2019 hyperthyroidism and orbitopathy in time of COVID-19 pandemic","volume":"43","author":"Bartalena","year":"2020","journal-title":"J Endocrinol Invest."},{"issue":"5","key":"2021122106321195000_CIT0204","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa148","article-title":"Our response to COVID-19 as Endocrinologists and Diabetologists","volume":"105","author":"Kaiser","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122106321195000_CIT0205","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12020-020-02294-5","article-title":"COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology","volume":"68","author":"Puig-Domingo","year":"2020","journal-title":"Endocrine."},{"issue":"9","key":"2021122106321195000_CIT0206","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021122106321195000_CIT0207","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","article-title":"The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study","volume":"19","author":"Paridaens","year":"2005","journal-title":"Eye (Lond)."},{"issue":"5","key":"2021122106321195000_CIT0208","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/IOP.0000000000000211","article-title":"Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease","volume":"30","author":"Ayabe","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg."},{"issue":"7","key":"2021122106321195000_CIT0209","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/S0041-1345(02)03538-8","article-title":"Mechanisms of action of mycophenolate mofetil in preventing chronic rejection","volume":"34","author":"Allison","year":"2002","journal-title":"Transplant Proc."},{"issue":"4","key":"2021122106321195000_CIT0210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"2021122106321195000_CIT0211","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/cen.13170","article-title":"Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy","volume":"86","author":"Ye","year":"2017","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"6","key":"2021122106321195000_CIT0212","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40618-019-01161-z","article-title":"Systemic safety analysis of mycophenolate in Graves\u2019 orbitopathy","volume":"43","author":"Lee","year":"2020","journal-title":"J Endocrinol Invest."},{"issue":"6","key":"2021122106321195000_CIT0213","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40618-016-0441-9","article-title":"Prospective, systematically recorded mycophenolate safety data in Graves\u2019 orbitopathy","volume":"39","author":"Riedl","year":"2016","journal-title":"J Endocrinol Invest."},{"issue":"2","key":"2021122106321195000_CIT0214","first-page":"81","article-title":"Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody","volume":"46","author":"Sanders","year":"2011","journal-title":"J Mol Endocrinol."},{"issue":"1","key":"2021122106321195000_CIT0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s13317-012-0028-1","article-title":"Blocking type TSH receptor antibodies","volume":"4","author":"Furmaniak","year":"2013","journal-title":"Auto Immun Highlights."},{"issue":"1","key":"2021122106321195000_CIT0216","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/thy.2018.0349","article-title":"A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves\u2019 orbitopathy","volume":"29","author":"Marcinkowski","year":"2019","journal-title":"Thyroid."},{"issue":"9","key":"2021122106321195000_CIT0217","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/en.2018-00306","article-title":"Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice","volume":"159","author":"Jansson","year":"2018","journal-title":"Endocrinology."},{"issue":"7","key":"2021122106321195000_CIT0218","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves\u2019 hyperthyroidism: a phase I study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid."},{"issue":"11","key":"2021122106321195000_CIT0219","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/ajt.13377","article-title":"A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion","volume":"15","author":"Cordoba","year":"2015","journal-title":"Am J Transplant."},{"issue":"12","key":"2021122106321195000_CIT0220","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"Am J Transplant."},{"issue":"3","key":"2021122106321195000_CIT0221","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz013","article-title":"A novel anti-CD40 monoclonal antibody, iscalimab, for control of graves hyperthyroidism-a proof-of-concept trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122106321195000_CIT0222","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122106321195000_CIT0223","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122106321195000_CIT0224","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122106321195000_CIT0225","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/EJE-16-0552","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: rituximab therapy for Graves\u2019 orbitopathy - lessons from randomized control trials","volume":"176","author":"Stan","year":"2017","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2021122106321195000_CIT0226","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves\u2019 orbitopathy","volume":"30","author":"P\u00e9rez-Moreiras","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg."},{"key":"2021122106321195000_CIT0227","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa646\/33783225\/dgaa646.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/12\/3704\/41829250\/dgaa646.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/12\/3704\/41829250\/dgaa646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T06:36:20Z","timestamp":1640068580000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/12\/3704\/5905591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":227,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,9,14]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa646","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,9,14]]}}}